Close

Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN
6. SHW
7. AAPL
8. IBM


Go back to Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients
(NASDAQ: AKRO) Delayed: 21.00 +0.21 (1.01%)
Previous Close $20.79    52 Week High $ 
Open $20.94    52 Week Low $ 
Day High $21.23    P/E N/A 
Day Low $20.74    EPS $ 
Volume 556,045